Skip to main content
OpenTrials
Completed

NCT Number: NCT05586373

Ibuprofen vs Dipyrone After C-section in Preeclampsia

The goal of this randomized, triple-masked clinical trial is to compare the effectiveness and safety of the use of ibuprofen versus dipyrone for postoperative analgesia in postpartum women with preeclampsia undergoing cesarean section.

The main question it aims to answer are:

* Postoperative pain is similar; * The frequency of acute kidney injury is similar.

Researchers will compare one group that will receive dipyrone and the other group that will receive ibuprofen to see if Postoperative pain are different between groups or development of acute kidney injury each group is different.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Specific objectives

In postpartum women with preeclampsia undergoing cesarean section randomized to receive treatment with ibuprofen versus dipyrone for postoperative analgesia, compare:

primary outcomes

  • Postoperative pain (mild, moderate, severe by visual analogue scale)
  • Development of acute kidney injury (serum creatinine 1.5 to 1.9 times baseline, or increase in serum creatinine by ≥0.3 mg/dL, or decrease in urine output to <0.5 mL/kg/ hour for six to 12 hours).

secondary outcomes

  • Average reduction of visual analogue scale scores;

2 Reduction of mean scores by algometer;

  • Need for rescue analgesic;
  • User satisfaction with the Likert scale;
  • Basic laboratory tests and their evolution: urea, creatine, uric acid, saline, potassium and chlorine, lactic dehydrogenase (DHL), aspartate transferase (AST), alanine transferase (ALT), total and fractions bilirubin and plaque;
  • Evolution of blood pressure in the puerperium;
  • Number of hypertensive peaks;
  • Need for maintenance antihypertensive treatment and number of drugs;
  • Allergic reactions;
  • Gastrointestinal side effects;
  • Time between postoperative and unassisted ambulation;
  • Length of hospital stay;
  • Compound maternal morbidity (eclampsia, acute weight edema, HELLP, difficulty hypertension, intracranial hemorrhage, renal function control and others);
  • Maternal death;
  • Costs related to analgesic medications.

The sample is 74 patients randomized into two groups: one group that will receive dipyrone and the other group that will receive ibuprofen. Randomization for the two groups will be performed according to a list of random numbers drawn up for that purpose by an employee who does not be involved with data collection, to ensure confidentiality in the allocation. From this list, sealed envelopes will be prepared, numbered sequentially, with each number, according to the randomization table, corresponding to the patient's group (dipyrone or ibuprofen).

For statistical analysis of the data, the domain statistical program will be used public Epi-info version 7, or higher versions. Tables will be distributed frequency distribution for categorical variables, calculating the mean and standard deviation of quantitative variables. Then, contingency tables will be used to determine the association of the independent variable (Ibuprofen versus dipyrone) with the dependent variables (Biological characteristics, obstetric features, Maternal clinical parameters at admission and during hospitalization, Maternal laboratory tests at the time of admission). For determination of the strength of association will be calculated as a measure of the risk (RR) and its 95% confidence interval. All p values will be two-tailed and in all stages of the analysis will be considered a level of significance 5%.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Puerperal women from 14 years of age diagnosed with preeclampsia with signs of severity Immediate postoperative period;
  • Delivery attended at the Maternity from Instituto de Medicina Integral Prof Fernando Figueira.

Exclusion criteria

  • Acute kidney disease (serum creatinine 1.5 to 1.9 times baseline, or increase in serum creatinine by ≥0.3 mg/dL, or decrease in urine output to <0.5 mL/kg/hour for six to 12 hours)
  • Chronic kidney disease;
  • Diabetes mellitus;
  • Collagenoses;
  • Sickle cell anemia;
  • Patients who presented bleeding in the pre, trans and immediate postpartum periods;
  • Antepartum or puerperal sepsis;
  • Known contraindications to the use of NSAIDs and dipyrone;

Treatment and study plan

medication 1

Drug

Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days

Other names: Ibuprofen 400 mg

medication 2

Drug

Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days

Other names: Dipyrone 1g

Primary outcomes

  1. Postoperative pain

    Time frame: from 24 after delivery to 48 hours

    Postoperative pain (mild, moderate, severe by visual analogue scale)

  2. Development of acute kidney injury

    Time frame: from 24 after delivery to 48 hours

    Development of acute kidney injury (serum creatinine 1.5 to 1.9 times baseline, or increase in serum creatinine by ≥0.3 mg/dL, or decrease in urine output to <0.5 mL/kg/ hour for six to 12 hours).

Secondary outcomes

  1. Mean reduction of pain scores by visual analogue scale;

    Time frame: from 24 after delivery to 48 hours

    Mean reduction of pain scores by visual analogue scale;

  2. Mean reduction in pain scores assessed by algometer

    Time frame: from 24 after delivery to 48 hours

    Mean reduction in pain scores assessed by algometer

  3. need for rescue analgesic therapy;

    Time frame: from 24 after delivery to 48 hours

    Quantify the number of times analgesic medication was requested, in addition to what is being offered in the study

  4. User satisfaction level

    Time frame: from 24 after delivery to 48 hours

    Likert scale, used in questionnaires, Participants choose from a variety of possible responses to a specific question or statement; responses usually include "strongly agree", "agree", "neutral", "disagree" and "strongly disagree".

  5. urea dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, urea measured in mg/dl at admission and up to 48 hours after admission.

  6. aspartate transferase dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, aspartate transferase dosage measured in mg/dl at admission and up to 48 hours after admission.

  7. potassium dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, potassium dosage measured in mg/dl at admission and up to 48 hours after admission.

  8. chlorine dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution,chlorine dosage measured in mg/dl at admission and up to 48 hours after admission.

  9. alanine transferase dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, alanine transferase dosage measured in mg/dl at admission and up to 48 hours after admission.

  10. lactic dehydrogenase dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, lactic dehydrogenase dosage measured in mg/dl at admission and up to 48 hours after admission.

  11. sodium dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, sodium dosage measured in mg/dl at admission and up to 48 hours after admission.

  12. creatinine dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, creatinine dosage measured in mg/dl at admission and up to 48 hours after admission.

  13. c

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution, creatinine dosage measured in mm³ at admission and up to 48 hours after admission.

  14. total and fractions bilirubin dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory tests and their evolution: urea, creatinine, uric acid, sodium, potassium and chlorine, lactic dehydrogenase (DHL), aspartate transferase (AST), alanine transferase (ALT), total and fractions bilirubin and platelets;

  15. uric acid dosage

    Time frame: from admission in the hospital until 48 hours after delivery

    Baseline laboratory test and the evolution. urea, creatinine, uric acid, sodium, potassium and chlorine, lactic dehydrogenase (DHL), aspartate transferase (AST), alanine transferase (ALT), total and fractions bilirubin and platelets;

  16. Evolution of blood pressure in the puerperium

    Time frame: from 24 after delivery to 48 hours

    Evolution of blood pressure in the puerperium

  17. Number of hypertensive peaks

    Time frame: from 24 after delivery until discharge of the hospital

    Number of hypertensive peaks (systolic blood pressure of 180mmHg and/or diastolic blood pressure of 120mmHg);

  18. need for maintenance antihypertensive treatment

    Time frame: from 24 after delivery until discharge of the hospital

    Identify the presence or absence of maintenance antihypertensive drugs

  19. number of antihypertensive drugs;

    Time frame: from 24 after delivery until discharge of the hospital

    quantify how many antihypertensive medications are being used

  20. Allergic reactions

    Time frame: from 24 after delivery to 48 hours

    Questionnaire with options for allergic manifestations: urticaria, angioedema, eczema, asthma.

  21. Gastrointestinal side effects

    Time frame: from 24 after delivery to 48 hours

    Questionnaire with options for acute gastrointestinal effects: abdominal pain, dyspepsia and diarrhea

  22. Time between postoperative and unassisted ambulation

    Time frame: from 24 after delivery to 48 hours

    Time between postoperative and unassisted ambulation

  23. Length of hospital stay

    Time frame: From hospital admission to hospital discharge date or up to eight days after surgery whichever comes first.

    Length of hospital stay

  24. Compound maternal morbidity

    Time frame: from 24 after delivery until discharge date or up to eight days after surgery whichever comes first.

    Compound maternal morbidity (eclampsia, acute pulmonary edema, HELLP syndrome, difficult-to-control hypertension, intracranial hemorrhage, renal failure and others);

  25. Maternal death

    Time frame: from 24 after delivery until discharge date or up to eight days after surgery whichever comes first.

    Space reserved in the questionnaire to be described according to the death certificate the primary cause of maternal death.

  26. Costs related to analgesic medications

    Time frame: from 24 after delivery until discharge date or up to eight days after surgery whichever comes first.

    Accounting for the cost related to each dose doses of anesthetic medications that were used in addition to the therapeutic regimens of the experiment were used

Sponsors and collaborators

Lead sponsor

Instituto Materno Infantil Prof. Fernando Figueira

Other

Registry information

Official study title

Use of Ibuprofen Versus Dipyrone in Preeclampsia Submitted to C-section: Randomized Clinical Trial

Acronym: DIPROFEN

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 19, 2022
Registry last updated
Jun 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.